People with relapsed or refractory diffuse large B-cell lymphoma who cannot have an autologous stem cell transplant usually have polatuzumab vedotin plus rituximab and bendamustine. The clinical evidence is from a small study that did not directly compare tafasitamab plus lenalidomide with any other trea...

Texto completo

Evidence-based recommendations on polatuzumab vedotin (Polivy) with rituximab, cyclophosphamide, doxorubicin and prednisolone for untreated diffuse large B-cell lymphoma in adults. Commercial arrangement There is a simple discount patient access scheme for polatuzumab vedotin. NHS organisations can get ...

Texto completo